Published 4 months ago

Haya Therapeutics, the biotech from Lausanne that won the billion dollar with the American Eli Lilly

Summary by Le Temps

Distinguished in 2023 as the most promising Swiss start-up, the Lausanne-based company has just announced a $1 billion agreement with the American laboratory. Recognition for its work on the “dark genome” Located at the Biopôle Campus in Lausanne, Haya Therapeutics was born in 2019, just before covid. Despite its young existence at the level of biotechs, the Vaud-based company has just taken a major step forward. On September 4, it announced the…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated4 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Haya Therapeutics, the biotech from Lausanne that won the billion dollar with the American Eli Lilly

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics